MedinCell Has Launched a Research Initiative to Formulate Injectable Ivermectin
April 7, 2020 at 7:04 am
(This post was last modified: April 7, 2020 at 7:22 am by Megabullshit.)
MedinCell Has Launched a COVID-19 Research Initiative Based on Its Experience to Formulate Long-Acting Injectable Ivermectin
Researchers at Monash University in Melbourne, Australia, have published last Friday a study showing that antiparasitic drug Ivermectin can kill coronavirus in a laboratory setting in under 48 hours. A single treatment is able to effect ∼5000-fold reduction in virus at 48h in cell culture.
Ivermectin has a long track record of use as a safe and effective drug to treat several parasitic diseases.
MedinCell has published data showing that long-acting formulations of Ivermectin can be designed with varying doses and durations with its BEPO® technology and is already leading a program aiming at developing a 3-Month injectable product to fight malaria.
MedinCell has launched a few weeks ago a research initiative on a long-acting injectable formulation of Ivermectin and believes it could have a role to play in Covid-19 management.
Future clinical studies will have to confirm the action of Ivermectin on Covid-19 virus, and the potential effectiveness of a long-acting injectable on its prevention and therefore breaking the chain of transmission.
In case of positive results, a BEPO® technology based long-acting injectable Ivermectin offers a rapidly deployable and affordable solution for a global pandemic.
https://www.businesswire.com/news/home/2...Experience
Researchers at Monash University in Melbourne, Australia, have published last Friday a study showing that antiparasitic drug Ivermectin can kill coronavirus in a laboratory setting in under 48 hours. A single treatment is able to effect ∼5000-fold reduction in virus at 48h in cell culture.
Ivermectin has a long track record of use as a safe and effective drug to treat several parasitic diseases.
MedinCell has published data showing that long-acting formulations of Ivermectin can be designed with varying doses and durations with its BEPO® technology and is already leading a program aiming at developing a 3-Month injectable product to fight malaria.
MedinCell has launched a few weeks ago a research initiative on a long-acting injectable formulation of Ivermectin and believes it could have a role to play in Covid-19 management.
Future clinical studies will have to confirm the action of Ivermectin on Covid-19 virus, and the potential effectiveness of a long-acting injectable on its prevention and therefore breaking the chain of transmission.
In case of positive results, a BEPO® technology based long-acting injectable Ivermectin offers a rapidly deployable and affordable solution for a global pandemic.
https://www.businesswire.com/news/home/2...Experience
